Accent Microcell Ltd · ACCENTMIC · Pharma - Formulators · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 16 May 2026
Accent Microcell share price today: ₹607.50 at the close on 18 November 2026, up 97.1% in a year. Accent Microcell (ACCENTMIC) is worth ₹1,457 crore, trades at a P/E of 25.6 and has closed between ₹308.20 and ₹725.75 over the past 52 weeks. Latest change: promoters cut their stake by 1.6 points in one quarter.
Accent Microcell Ltd's share price has risen faster than its earnings: +97.1% in a year, against +58.0% for earnings per share.
The main question: profits are rising, but only 51% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.
The price has been rising for 70 weeks, and the P/E is higher than 66% of its own last 2.9 years. Over the last four quarters, results have been improving, with profit +72.2% on a year earlier, and 51% of the last 3 years' profit came in as cash. What will decide it: whether the cash starts to follow the profit.
What is the Accent Microcell share price today?
Accent Microcell Ltd's share price was ₹607.50 at the close on 18 November 2026. It has been rising for 70 weeks. That is 17.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹308 and ₹726, and at that close it sat 72% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Accent Microcell Ltd is in stage 2. The phase helps read everything below.
Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.
Week by week since 2023: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 91 of 149 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 15 Dec 2023 | no NIFTY 500 reading |
| 22 Dec 2023 | no NIFTY 500 reading |
| 29 Dec 2023 | no NIFTY 500 reading |
| 5 Jan 2024 | no NIFTY 500 reading |
| 12 Jan 2024 | no NIFTY 500 reading |
| 20 Jan 2024 | no NIFTY 500 reading |
| 25 Jan 2024 | no NIFTY 500 reading |
| 2 Feb 2024 | no NIFTY 500 reading |
| 9 Feb 2024 | no NIFTY 500 reading |
| 16 Feb 2024 | no NIFTY 500 reading |
| 23 Feb 2024 | no NIFTY 500 reading |
| 2 Mar 2024 | no NIFTY 500 reading |
| 7 Mar 2024 | no NIFTY 500 reading |
| 15 Mar 2024 | −28.5% |
| 22 Mar 2024 | −17.3% |
| 28 Mar 2024 | −20.2% |
| 5 Apr 2024 | −26.8% |
| 12 Apr 2024 | −23.3% |
| 19 Apr 2024 | −18.3% |
| 26 Apr 2024 | −19.9% |
| 3 May 2024 | −11.2% |
| 10 May 2024 | +3.8% |
| 18 May 2024 | +14.9% |
| 24 May 2024 | −0.4% |
| 31 May 2024 | −4.1% |
| 7 Jun 2024 | −6.6% |
| 14 Jun 2024 | +9.0% |
| 21 Jun 2024 | −0.9% |
| 28 Jun 2024 | +1.3% |
| 5 Jul 2024 | −3.7% |
| 12 Jul 2024 | +2.0% |
| 19 Jul 2024 | −4.2% |
| 26 Jul 2024 | −4.2% |
| 2 Aug 2024 | −5.7% |
| 9 Aug 2024 | −19.0% |
| 16 Aug 2024 | −27.0% |
| 23 Aug 2024 | −11.2% |
| 30 Aug 2024 | −8.9% |
| 6 Sep 2024 | −8.1% |
| 13 Sep 2024 | −9.5% |
| 20 Sep 2024 | −10.9% |
| 27 Sep 2024 | −6.3% |
| 4 Oct 2024 | −3.1% |
| 11 Oct 2024 | −7.4% |
| 18 Oct 2024 | −6.4% |
| 25 Oct 2024 | −6.3% |
| 1 Nov 2024 | −6.2% |
| 8 Nov 2024 | −4.5% |
| 14 Nov 2024 | −6.4% |
| 22 Nov 2024 | −10.1% |
| 29 Nov 2024 | −3.6% |
| 6 Dec 2024 | −2.1% |
| 13 Dec 2024 | −5.5% |
| 20 Dec 2024 | −2.2% |
| 27 Dec 2024 | +4.9% |
| 3 Jan 2025 | +6.3% |
| 10 Jan 2025 | +2.5% |
| 17 Jan 2025 | +5.6% |
| 24 Jan 2025 | +7.3% |
| 1 Feb 2025 | +4.5% |
| 7 Feb 2025 | +5.7% |
| 14 Feb 2025 | +6.6% |
| 21 Feb 2025 | +3.1% |
| 28 Feb 2025 | −3.1% |
| 7 Mar 2025 | −5.8% |
| 13 Mar 2025 | −9.1% |
| 21 Mar 2025 | −11.5% |
| 28 Mar 2025 | −25.3% |
| 4 Apr 2025 | −24.0% |
| 11 Apr 2025 | −19.4% |
| 17 Apr 2025 | −21.7% |
| 25 Apr 2025 | −19.6% |
| 2 May 2025 | −22.6% |
| 9 May 2025 | −20.1% |
| 16 May 2025 | −14.1% |
| 23 May 2025 | −2.5% |
| 30 May 2025 | −6.5% |
| 6 Jun 2025 | −1.8% |
| 13 Jun 2025 | +7.7% |
| 20 Jun 2025 | +3.8% |
| 27 Jun 2025 | +16.5% |
| 4 Jul 2025 | +33.0% |
| 11 Jul 2025 | +32.6% |
| 18 Jul 2025 | +31.8% |
| 25 Jul 2025 | +27.1% |
| 1 Aug 2025 | +57.3% |
| 8 Aug 2025 | +48.3% |
| 14 Aug 2025 | +32.4% |
| 22 Aug 2025 | +27.2% |
| 29 Aug 2025 | +28.9% |
| 5 Sep 2025 | +22.9% |
| 12 Sep 2025 | +14.0% |
| 19 Sep 2025 | +20.8% |
| 26 Sep 2025 | +10.4% |
| 3 Oct 2025 | −7.4% |
| 10 Oct 2025 | −8.8% |
| 17 Oct 2025 | +1.3% |
| 24 Oct 2025 | −3.9% |
| 31 Oct 2025 | −16.3% |
| 7 Nov 2025 | −10.8% |
| 14 Nov 2025 | +1.1% |
| 21 Nov 2025 | −0.5% |
| 28 Nov 2025 | +8.6% |
| 5 Dec 2025 | +14.9% |
| 12 Dec 2025 | +26.1% |
| 19 Dec 2025 | +23.8% |
| 26 Dec 2025 | +25.6% |
| 2 Jan 2026 | +38.5% |
| 9 Jan 2026 | +38.2% |
| 16 Jan 2026 | +23.0% |
| 23 Jan 2026 | +22.7% |
| 1 Feb 2026 | +23.4% |
| 6 Feb 2026 | +17.7% |
| 13 Feb 2026 | +6.5% |
| 20 Feb 2026 | +10.4% |
| 27 Feb 2026 | +10.3% |
| 6 Mar 2026 | +8.8% |
| 13 Mar 2026 | +11.6% |
| 20 Mar 2026 | +17.2% |
| 27 Mar 2026 | +28.0% |
| 2 Apr 2026 | +22.2% |
| 10 Apr 2026 | +23.2% |
| 17 Apr 2026 | +27.4% |
| 24 Apr 2026 | +36.0% |
| 30 Apr 2026 | +29.7% |
| 8 May 2026 | +43.8% |
| 15 May 2026 | +40.5% |
| 22 May 2026 | +33.4% |
| 29 May 2026 | +28.3% |
| 4 Jun 2026 | +37.7% |
| 5 Jun 2026 | +33.2% |
| 9 Jun 2026 | +26.8% |
| 10 Jun 2026 | +16.7% |
| 12 Jun 2026 | +12.8% |
| 17 Jun 2026 | +0.8% |
| 19 Jun 2026 | +3.1% |
| 24 Jun 2026 | +4.1% |
| 25 Jun 2026 | +6.2% |
| 1 Jul 2026 | +4.8% |
| 3 Jul 2026 | +9.7% |
| 10 Jul 2026 | +14.6% |
| 17 Jul 2026 | +13.2% |
| 24 Jul 2026 | +2.8% |
| 31 Jul 2026 | +2.0% |
| 7 Aug 2026 | +9.4% |
| 14 Aug 2026 | +22.1% |
| 21 Aug 2026 | +27.6% |
| 28 Aug 2026 | +37.5% |
| 4 Sep 2026 | +36.2% |
| 11 Sep 2026 | +57.4% |
| 18 Sep 2026 | +49.5% |
| 25 Sep 2026 | +39.0% |
| 28 Sep 2026 | +38.4% |
| 1 Oct 2026 | +36.9% |
| 9 Oct 2026 | +32.9% |
| 16 Oct 2026 | +39.3% |
| 23 Oct 2026 | +25.3% |
| 30 Oct 2026 | +25.1% |
| 6 Nov 2026 | +5.4% |
| 8 Nov 2026 | +2.8% |
| 13 Nov 2026 | +0.5% |
| 18 Nov 2026 | −3.7% |
Over the last 2.9 years the share price moved +104% while the NIFTY 500 moved +24%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 13 November 2026. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Accent Microcell this quarter?
6 points in one quarter, profit up on a year earlier for 5 quarters in a row (every quarter we can compare) and operating margin up 7 points on a year earlier.
Promoters cut their stake by 1.6 points in one quarter
From 53% to 51.4% in the September 2026 quarter.
Profit up on a year earlier for 5 quarters in a row (every quarter we can compare)
In the September 2026 quarter profit was ₹31 crore, +72.2% on a year earlier.
Operating margin up 7 points on a year earlier
24% in the September 2026 quarter, from 17%.
What are Accent Microcell's latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Accent Microcell reported revenue of ₹175 crore, up 25.9% from ₹139 crore a year earlier, and a profit of ₹31.0 crore, up 72.2% from ₹18.0 crore.
Accent Microcell results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹175 crore | ₹139 crore | +25.9% |
| Profit | ₹31.0 crore | ₹18.0 crore | +72.2% |
| Earnings per share | ₹12.97 | ₹7.53 | +72.2% |
| Operating margin | 23.4% | 17.3% | +6.1 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
The newest call in our records is from 16 May 2026, about January to March 2026; a call about these results is not in our records yet.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Accent Microcell share price history?
Accent Microcell closed at ₹607.50 on 18 November 2026, up 97.1% from ₹308.20 a year earlier (21 November 2025) and up 103.9% over three years. Its highest weekly close since December 2023 was ₹725.75 on 11 September 2026.
Accent Microcell share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹603.90 | +0.6% |
| 1 month ago · 19 Oct 2026 | ₹654.40 | −7.2% |
| 6 months ago · 15 May 2026 | ₹441.25 | +37.7% |
| 1 year ago · 21 Nov 2025 | ₹308.20 | +97.1% |
| 3 years ago · 15 Dec 2023 | ₹297.96 | +103.9% |
| Earliest weekly close in our records · 15 Dec 2023 | ₹297.96 | +103.9% |
| Highest weekly close since December 2023, also the 52-week high · 11 Sep 2026 | ₹725.75 | −16.3% |
| Lowest weekly close since December 2023 · 28 Mar 2025 | ₹180.53 | +236.5% |
| 52-week low (weekly close) · 21 Nov 2025 | ₹308.20 | +97.1% |
Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
162 weekly closes from 15 December 2023 to 18 November 2026.
What is the latest news on Accent Microcell?
18 Nov 2026: Accent Microcell closed at ₹607.50, up 0.6% on the week and down 7.2% on the month. Results for July to September 2026: Revenue up 25.9% and profit up 72.2% on a year earlier.
Earlier
- 16 May 2026: Accent Microcell held its results call for January to March 2026.
What dividend does Accent Microcell pay?
The exchange corporate-actions record has no dividend for Accent Microcell since its first close in our records (15 December 2023), so this page cannot show amounts per share.
Yes. Accent Microcell Ltd paid out 5% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 8 reported years.
From the exchange corporate-actions record, read 18 November 2026.
What to watch in Accent Microcell's next results?
When Accent Microcell reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier.
- Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was +25.9% on a year earlier, and the last four quarters averaged +21.8%.
- Whether the operating margin stays near 23.4%. The latest full year's operating margin was the highest on file. Every ratio built on profit looks better at a peak.
- Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +72.2% on a year earlier. It has grown on a year earlier for 5 quarters in a row.
- Whether cash from operations catches up with profit. Only 51% of the last 3 years' profit came in as cash from operations.
Which stock lists is Accent Microcell on?
Accent Microcell is on 2 of our India lists: Momentum stocks and Pharma stocks.
Is Accent Microcell profitable?
Accent Microcell Ltd earned ₹31.0 Cr of net profit in the Sep 2026 quarter, +72.2% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹44.0 Cr. Over 7 years profit has grown 40.9% a year on average. The same quarter a year earlier earned ₹16.0 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The Sep 2026 quarter's profit is 17.7% of that quarter's revenue.
For the full year, FY26 profit was ₹44.0 Cr (+33.3% on the year before).
Why profit moved: revenue changed +25.9% on a year earlier and the margin moved +6.1 percentage points. Most of the change came from keeping more of each sale.
On average over the last four quarters, profit changed +36.0% and revenue +21.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.
How much revenue does Accent Microcell make, and is it growing?
Accent Microcell Ltd reported ₹175 Cr of revenue in the Sep 2026 quarter, +25.9% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 7 years it has grown 17.3% a year on average. The last full year, FY26, came in at ₹349 Cr.
Revenue is everything the company billed its customers in the period.
Why this happened. Regulated market export is the structural revenue quality upgrade. Dahej SEZ spray-dryer produces pharma-grade MCC accepted in regulated markets. Export revenue is higher-margin than domestic (Rs 170-190/kg domestic vs premium-priced Dahej exports). The zero China supply chain exposure (USA, Sweden, Canada, Indonesia sourcing) is a genuine competitive moat in current geopolitical context. Phase 2 (MCC export line, March 2027 goal) specifically goals established 20+ year customer relationships for high utilization from Year 1.
FY26 revenue was ₹349 Cr, +31.7% on the year before.
Recent pace: the last four quarters grew +21.8% on average, against 17.3% a year over the longer run, so this year is growing faster than its own long-run rate.
Watch next
- Metric
- Geographical Expansion (60% export, 45+ countries…
- Threshold
- June 25, 2026 Phase 1 commercialization announcement, silence past July 15 = red flag
- Which result
- the next result
How much of every ₹100 of sales does Accent Microcell keep?
Accent Microcell Ltd's operating margin was 23.4% in the Sep 2026 quarter, 6.1 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved +8.3 percentage points. Across 8 years it has been between 5.3% and 16.3%.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
The latest quarter is above every full year in that period.
Why the margin moved: operating margin changed +8.8 percentage points on the year while gross margin changed +10.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged.
When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.
Is Accent Microcell's profit turning into cash?
Over the last 3 years, 51% of Accent Microcell Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹19.0 Cr of operating cash against ₹44.0 Cr of profit. After ₹88.0 Cr of spending on assets, free cash was −₹69.0 Cr: it spent more than its operations brought in.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 51% of profit came in as cash: the cash cycle got 29 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.
What to look at next: less of the profit turns into cash than it should, and the cash cycle is 29 days longer. The next section looks at where the cash is stuck.
Where does Accent Microcell's cash go?
Accent Microcell Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 117 days in FY26, up from 88 days in FY21. It spent ₹138 Cr on assets over the last 3 years. Customers take 95 days to pay, and stock sits for 55 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹349 Cr, each day of that cycle ties up about ₹1.0 Cr, so roughly ₹112 Cr is tied up in the business at any time.
FY26: customers took 95 days to pay and stock sat for 55 days, about 1.8 months of sales sitting as stock, for a full cycle of 117 days, longer than FY21's 88.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 55 days. Customers pay about 95 days after that. Suppliers are paid at 33 days. Together that makes the 117-day cycle.
Spending on assets: ₹138 Cr over the last 3 years, against ₹13.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹102 Cr (FY26): assets paid for that are not earning yet.
In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.
What is Accent Microcell's P/E ratio, and how does it compare with its own history?
Accent Microcell Ltd's P/E is 25.6×, in the middle of its own history: higher than 66% of past readings. Its usual P/E (the middle reading) is 22.6×, over 2.9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
Why this happened. FY26 blended PAT margin was held at 16% by trading dilution, manufacturing segment implicit margin was 20%+. Eliminating or substantially reducing the Rs 90 Cr trading book (which exists purely to retain customer relationships during the approval cycle) would structurally lift blended OPM toward 18-20% as guided. This is not a new catalyst, it is the unwinding of a temporary drag, but it is a meaningful tailwind if Phase 2 executes on schedule.
Why the multiple is where it is: over the past year earnings per share moved +58.0% while the price moved +97.1%. The price did better than earnings, which pushed the multiple up within its own range.
In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.
Watch next
- Metric
- Trading Revenue Exit + Manufacturing Margin Expansion
- Threshold
- June 25, 2026 Phase 1 commercialization announcement, silence past July 15 = red flag
- Which result
- the next result
Is the Accent Microcell business getting better or worse?
Accent Microcell Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 5 quarters of 1 measure, with some gaps.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: with too little history, we say so rather than guess a direction.
One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.
There are fewer than eight usable quarters, so this page does not guess a direction from so little history.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +31.7% | +21.0% | +21.3% | — |
| Profit | +33.3% | +54.2% | +54.5% | — |
| EPS | +22.8% | +27.0% | +38.7% | — |
| Share price | +97.1% | — | — | — |
What is the Accent Microcell story, and has it been checked?
Accent Microcell Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: first time expansion 5y.
NOT YET CHECKED
From the numbers. At 73rd percentile (median 20.4x)…
From the price. Price stage 2, week 70, above its 200-day line, relative strength falling.
What is not proven yet. Phase 1 already 8-9 months late; GPCB approval actively denied in May 2025 but was primary delay cause; June 25, 2026 goal is contingent on regulatory receipt, another slip would be the 4th documented failure.
The test written in advance. Management credibility, Unit 3 delayed again (3rd miss). Measured by: Management credibility, Unit 3 delayed again (3rd miss) June 25, 2026 Phase 1 commercialization announcement, silence past July 15 = red flag by the next result.
The test written in advance. Wood pulp and alpha cellulose input cost volatility. Measured by: Wood pulp and alpha cellulose input cost volatility Quarterly OPM below 15% = input cost headwind materialising by the next result.
The key numbers to watch, and the level that would change the picture
| Measure | Now | Why it matters |
|---|---|---|
| Premium Product Mix Shift (CCS + silicated… | HIGH | Premium products at 13% of FY26 revenue at 3x average realization (Rs 600-900/kg vs Rs 260/kg blended), Unit 3 Phase 1 adds… |
| Geographical Expansion (60% export, 45+… | MEDIUM HIGH | |
| Unit 3 Phase 1 Capacity Ramp (2,400 MT, Rs… | HIGH | 2,400 MT fungible capacity (CCS/CMC/silicated MCC) with Rs 150 Cr peak revenue potential at Rs 600-700/kg, contingent on… |
| Trading Revenue Exit + Manufacturing… | MEDIUM | Rs 90 Cr (26% revenue) trading at 2-6% margin planned for substantial reduction post Phase 2; exit improves blended PAT margin… |
| DII Accumulation + Growing Institutional… | LOW | DII stake grew from 1.62% (Mar 2024) to 3.57% (Dec 2025), quiet institutional accumulation at sub-1,100 Cr MCap. |
Everything further down this page is evidence for or against these.
FY25-Q2FY26-Q4
- 1 · Operating leveragequiet
- 2 · Value-added mixquiet
- 3 · Management changequiet
- 4 · Paying down debtquiet
- 5 · Regulatory approvalquiet
- 6 · Order-book winsbuilding
- 7 · Consolidationquiet
- 8 · Demerger or value unlockbuilding
- 9 · Buybackbuilding
- 10 · New geographiesbuilding
- 11 · More business from existing customersquiet
- 12 · New product launchquiet
- 13 · Mandatory normsquiet
- 14 · A bigger market to servequiet
- 15 · Market-share gainsbuilding
- 16 · Asset qualityquiet
Lever 9 · Buyback: building. Premium products at 13% of FY26 revenue at 3x average realization (Rs 600-900/kg vs Rs 260/kg blended), Unit 3 Phase 1 adds 2,400 MT dedicated premium capacity from June 2026. What proves it keeps working: Premium Product Mix Shift (CCS + silicated MCC + MCC Spheres). It stops working if June 25, 2026 Phase 1 commercialization announcement, silence past July 15 = red flag.
Lever 10 · New geographies: building. What proves it keeps working: Geographical Expansion (60% export, 45+ countries, regulated market penetration).
Lever 6 · Order-book wins: building. 2,400 MT fungible capacity (CCS/CMC/silicated MCC) with Rs 150 Cr peak revenue potential at Rs 600-700/kg, contingent on GPCB/CTO/CCA approvals by June 25, 2026. What proves it keeps working: Unit 3 Phase 1 Capacity Ramp (2,400 MT, Rs 150 Cr peak revenue).
Lever 8 · Demerger or value unlock: building. Rs 90 Cr (26% revenue) trading at 2-6% margin planned for substantial reduction post Phase 2; exit improves blended PAT margin by 200-300 bps mechanically. What proves it keeps working: Trading Revenue Exit + Manufacturing Margin Expansion.
Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
Did Accent Microcell management deliver what it promised?
What Accent Microcell Ltd's management promised, against what actually happened: 3 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Unit 3 Phase 1 Commercialization Delay · 16 May 2026. Management committed during the May 2025 call to commencing commercial production for Unit 3 Phase 1 by September or October 2025. However, in the May 2026 call, the facility was revealed to still be non-operational, with management providing a new tentative launch date of late June or July 2026, representing an eight to nine-month delay from original projections.
Unit 3 Phase 2 Timeline Revision · 16 May 2026. In the May 2025 call, management projected that Phase 2 of Unit 3 would be commercialized by approximately June 2026. By the May 2026 call, this timeline was significantly delayed to March 2027, a nearly one-year postponement for a project previously characterized as a straightforward brownfield expansion.
Contradictory Disclosures on Environmental Clearances · 16 May 2026. During the May 2025 call, management explicitly denied that any environmental or Pollution Control Board approvals were pending for Unit 3, stating that no such issues existed. Conversely, in the May 2026 call, management admitted that the extensive delays in commercialization were primarily due to unfinished licensing and pending approvals from the Gujarat Pollution Control Board (GPCB).
Every quote above is taken word for word from the company’s own earnings calls.
What is Accent Microcell management's track record?
Accent Microcell (ACCENTMIC) shows strong margin discipline but a delay in capital expenditure execution. For FY25, the company reported revenue of ₹273.86 Cr (up 11% on a year earlier) and profit of ₹33.06 Cr, missing the high-growth trajectory of FY24 (24% revenue growth). While management initially guided for the Unit-III (Nayka Kheda) facility to be operational by April 2025, latest reports from March 2026 indicate the 12,000 MTPA expansion is now expected by November 2026. However, operational efficiency remains high, with PBILDT margins improving from 16% in FY25 to 17.83% in H1 FY26, outperforming sector averages.
Regulatory and governance record
Accent Microcell Ltd (ACCENTMIC) maintains a clean record with SEBI, CBI, and ED, with no fraud or insider trading actions reported as of April 2026. However, a significant regulatory red flag exists regarding environmental compliance. Per a June 2025 disclosure, the National Green Tribunal (NGT) issued an order on February 2, 2022, having the company responsible for statutory violations related to wastewater and hazardous waste handling. The estimated compensation (penalty) was ₹4.116 Cr. The matter remains sub-judice at the NGT Pune Bench, with the last hearing in April 2025 and a subsequent date in July 2025. No disciplinary actions by SEBI or stock exchanges were recorded in the five fiscals preceding 2025.
Checked 20 April 2026.
How much does Accent Microcell earn on its capital?
Accent Microcell Ltd earned a ROCE of 25% in FY26. That is up from a low of 17% in FY21. Its return on capital used (ROIC) is 6.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.6% net margin and 1.08× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 12.6% net margin × 1.08× asset turnover × 1.17× leverage (assets divided by equity) ≈ 15.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.
The key test, return on capital used minus the cost of capital: 18.7% − 12.0% = +6.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
The 18.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 20.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
Does Accent Microcell have too much debt?
Accent Microcell Ltd has total debt of ₹1.0 Cr against shareholder equity of ₹304 Cr as of Sep 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.08 in FY24 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
What is the Accent Microcell shareholding pattern?
Promoters cut their stake in Accent Microcell Ltd by 3.7 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 51.4% of the company. Domestic institutions moved +0.8 points over the same period, to 2.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Why this happened. The core structural thesis. Accent's differentiation from commodity MCC is the pulp-based CCS process (8-year R&D, first commercial India deployment) and spray-dryer Dahej technology. H2 FY26 showed premium products accelerating to 13% of revenue with silicated MCC and MCC Spheres both scaling. Phase 1 (2,400 MT) is fungible across CCS/CMC/silicated MCC, once operational, it unlocks the 16-17% FY27 premium mix goal. The realization differential (Rs 600-700/kg for CCS vs Rs 260/kg base) means even modest Phase 1 volumes are highly PAT-accretive. The risk is the Phase 1 delay record.
Over the last two years: Promoters: −3.7 points over 8 quarters, to 51.4%; Domestic institutions: +0.8 points over 8 quarters, to 2.4%; Foreign institutions: +0.7 points over 8 quarters, to 0.7%.
Why the owners changed: promoters drove it (−3.7 points), with the other side taken by domestic institutions (+0.8 points). They reduced their stake.
Watch next
- Metric
- Premium Product Mix Shift (CCS + silicated MCC + MCC…
- Threshold
- June 25, 2026 Phase 1 commercialization announcement, silence past July 15 = red flag
- Which result
- the next result
How far is Accent Microcell from balance-sheet trouble?
For Accent Microcell Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Accent Microcell rank in its industry?
66.2 out of 100, rank 5 of 44 in Pharma - Formulators, with 65% of the evidence available.
Accent Microcell Ltd scores 66.2 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
The four parts add up to the total exactly: 21.8 + 21.6 + 10.1 + 12.7 = 66.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Accent Microcell compared with?
Accent Microcell ranks 5 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 66.2 out of 100.
- 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100
How the score adds up
Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100
How the score adds up
Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Kwality Pharmaceuticals LtdKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100
How the score adds up
Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 4Rubicon Research LtdRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100
How the score adds up
Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5Accent Microcell Ltd this pageACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Ajanta Pharma LtdAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100
How the score adds up
Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. - 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100
How the score adds up
Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100
How the score adds up
Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100
How the score adds up
Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100
- 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100
- 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100
- 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100
- 15Lupin LtdLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100
- 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100
- 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100
- 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100
- 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100
- 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100
- 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100
- 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100
- 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100
- 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100
- 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100
- 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100
- 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100
- 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100
- 29J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100
- 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100
- 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100
- 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100
- 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100
- 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100
- 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100
- 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100
- 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100
- 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100
- 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100
- 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100
- 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100
- 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100
- 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100
- 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharma - Formulators, all 44 compared on one page.
Which companies are close to Accent Microcell in size?
Accent Microcell is the 37th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Sai Parenterals, Bharat Parenterals and Amrutanjan Health Care. Just below it: Bafna Pharmaceuticals, Bajaj Healthcare and Lincoln Pharmaceuticals.
Pharma - Formulators companies close in size
- Sai Parenterals Ltd ₹2,217 crore
- Bharat Parenterals Ltd ₹1,682 crore
- Amrutanjan Health Care Ltd ₹1,493 crore
- Accent Microcell Ltd ₹1,457 crore
- Bafna Pharmaceuticals Ltd ₹1,112 crore
- Bajaj Healthcare Ltd ₹1,078 crore
- Lincoln Pharmaceuticals Ltd ₹1,031 crore
All 44 Pharma - Formulators companies, largest first
Companies close in size in other industries
- Accelya Solutions India Ltd ₹1,459 crore · IT Product Companies
- Eimco Elecon (India) Ltd ₹1,458 crore · Capital Goods - Engineering Heavy
- Accent Microcell Ltd ₹1,457 crore
- Capacite Infraprojects Ltd ₹1,455 crore · Realty - Construction & Contracting
- Blue Cloud Softech Solutions Ltd ₹1,454 crore · IT - Software
What else do people ask about Accent Microcell?
What were Accent Microcell's latest quarterly results?
Accent Microcell Ltd reported revenue of ₹175 Cr and net profit of ₹31.0 Cr for the Sep 2026 quarter. Revenue rose 25.9% and profit rose 72.2% compared with a year earlier. Earnings per share were ₹12.97.
The operating margin was 23.4%, 6.1 percentage points higher than a year earlier (as of 18 November 2026).
What is Accent Microcell's market cap?
Accent Microcell Ltd's market capitalisation is ₹1,457 Cr at a share price of ₹607.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
How is Accent Microcell performing?
Accent Microcell Ltd's share price has been rising for 70 weeks. In its latest quarter, revenue rose 25.9% and profit rose 72.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 18 November 2026).
Will Accent Microcell's share price go up?
This page does not forecast Accent Microcell Ltd's share price. What it shows instead: the share price is ₹607.50, and it has been rising for 70 weeks. Its P/E of 25.6× is higher than 66% of its own last 3 years (as of 18 November 2026).
Who owns Accent Microcell?
Promoters own 51.4% of Accent Microcell Ltd, foreign institutions 0.7%, domestic institutions 2.4% and the public 45.5% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 3.7 percentage points over 8 quarters (as of 18 November 2026).
Does Accent Microcell have too much debt?
No, Accent Microcell Ltd has little debt: its debt is 0.00× its equity, and its operating profit is 59 times its interest bill. At Sep 2026 borrowings were ₹1.0 Cr against equity of ₹304 Cr.
So the returns on this page come from the business, not borrowed money (as of 18 November 2026).
Where is Accent Microcell in its business cycle?
Accent Microcell Ltd's FY26 operating margin was 16.3%, against a 8-year range of 5.3% to 16.3%. The latest quarter was 23.4%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Accent Microcell story?
The main question: profits are rising, but only 51% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Accent Microcell a stock worth studying right now?
What the numbers show: Accent Microcell Ltd's share price has risen faster than its earnings: +97.1% in a year, against +58.0% for earnings per share. The main open question: whether the cash starts to follow the profit.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.